Spotlight On... Massachusetts AG threatens legal action against Gilead over pricey hep C meds; U.K. cost watchdogs green-light cancer meds from AZ, Bayer, Astellas and Novartis but shoot down Lilly's; and more...

Gilead Sciences ($GILD) faces legal action in Massachusetts if it doesn't cut the prices of its hepatitis C drugs. State Attorney General Maura Healey warned CEO John Martin that the cost of Sovaldi and Harvoni--with list prices of $84,000 and $94,500--could violate Massachusetts laws against unfair trade practices. More from FiercePharma

> U.K. cost watchdogs have given a final thumbs-up to AstraZeneca's ($AZN) Lynparza, Bayer's Xofigo, Astellas' Xtandi and Novartis' ($NVS) Farydak. Report

>  The U.K.'s National Institute of Health and Care Excellence (NICE) remains unconvinced that Eli Lilly's ($LLY) stomach cancer med Cyramza is worth its price. Report

> According to J&J ($JNJ) CEO Alex Gorsky, the healthcare industry's investment in patient support programs and other value-added services is still in the "early innings." Report

> Cost regulators in the U.K. have approved routine use of Boehringer Ingelheim's Ofev as a treatment for some patients with idiopathic pulmonary fibrosis (IPF). Report

And Finally... A government-appointed health panel is calling for depression screenings during and after pregnancy. Report (sub. req.)


Suggested Articles

The FDA wants to know what, exactly, is in a drug name—and whether it influences how the product is perceived. So it's launching a study to find out.

Horizon Therapeutics has notched an FDA approval for its rare eye disease med Tepezza (teprotumumab), a possible blockbuster drug in the making.

After Clovis’ Rubraca snagged an FDA boost in prostate cancer last week, AZ and Merck’s rival Lynparza has matched it with a boost of its own.